Chronic Myelogenous Leukemia
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
What is Chronic Myelogenous Leukemia (CML)?
Leukaemia is cancer of the white blood cells. There are essentially two broad categories of leukemia – acute and chronic.
Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19).
Native to the southeastern United States, a weedy grass has spread northward to Canada and also made its way to Australia and Japan. Andropogon virginicus grows densely packed and up to seven feet tall, disrupting growth patterns of other plants and competing for resources.
Researchers have identified a second path to defeating chronic myelogenous leukemia, which tends to affect older adults, even in the face of resistance to existing drugs.
Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.
Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival.
Proteins commonly known as BRCA - short for BReast CAncer susceptibility gene- serve a critical role in cellular DNA repair, but when mutated they allow genetic errors to replicate, facilitating cancer development.
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.
A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.
The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.
This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.
Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.
Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease.
A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies.
Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States.
It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.
The National Comprehensive Cancer Network has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks™ for Breast, Colon, Kidney, and Rectal Cancers.
Health experts at Johns Hopkins Medicine are calling on lawmakers and regulators to close loopholes in the Orphan Drug Act they claim give drug companies millions of dollars in unintended and misplaced subsidies and tax breaks and fuel skyrocketing medication costs.